In Vitro Modelling of Osteogenesis Imperfecta with Patient-Derived Induced Mesenchymal Stem Cells

Area of Science:

• Stem cell biology
• Regenerative medicine
• Genetics and rare diseases

Background:

• Osteogenesis Imperfecta (OI) is a genetic disorder causing bone fragility, often studied using mesenchymal stem cells (MSCs).
• Existing models have limitations, necessitating novel approaches for better understanding OI bone pathology.

Purpose of the Study:

• To generate a novel Osteogenesis Imperfecta (OI) induced mesenchymal stem cell (iMSC) model.
• To utilize induced pluripotent stem cells (iPSCs) derived from human fibroblasts for OI iMSC generation.
• To establish a new protocol for OI iMSC generation via an intermediate induced neural crest cell (iNCC) stage.

Main Methods:

• Reprogramming skin fibroblasts from OI patients and healthy controls into induced pluripotent stem cells (iPSCs).
• Differentiating iPSCs into induced neural crest cells (iNCCs) and subsequently into induced mesenchymal stem cells (iMSCs).
• Confirming cell identity and differentiation potential using marker expression (SOX2, NANOG, OCT4, P75NTR, TFAP2A, HNK-1, CD73, CD105, CD90) and trilineage differentiation assays.

Main Results:

• Successfully generated iPSCs confirmed by morphology, pluripotency markers, and germ-layer differentiation.
• Established an intermediate iNCC stage characterized by specific marker expression.
• Generated iMSCs confirmed by MSC markers and trilineage differentiation capacity into osteoblasts, adipocytes, and chondrocytes.

Conclusions:

• A novel multipotent in vitro iMSC model for Osteogenesis Imperfecta (OI) has been developed.
• This model, derived from OI patients and healthy controls, is capable of differentiating into osteoblast-like cells.
• The iNCC intermediate stage represents a new strategy for generating patient-specific iMSCs for OI research.